Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia

  title={Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia},
  author={Clas F. R. K{\"a}llander and Bengt Simonsson and J. Simon Gronowitz and Kenneth Nilsson},
  journal={European Journal of Haematology},
The serum thymidine kinase (S‐TK) and proliferative activity of the leukemic cells were determined in 27 untreated patients with chronic lymphocytic leukemia (CLL). A significant positive correlation between S‐TK and proliferation expressed as a proliferative index (PI) was found (r = 0.70, p < 0.001). Additionally, PI (r = 0.59, p < 0.01) and S‐TK (r = 0.47, p < 0.05) correlated to peripheral blood lymphocyte count. When different variables and combinations of variables were studied in order… 

Activity of serum thymidine kinase in non-Hodgkin lymphoma: Relationship to other prognostic factors

The results indicate that TK might be a worthful parameter to estimate progression and response to therapy of NHL and correlated better with Binet stages than blood sedimentation rate.

Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors

It was showed that serum TK1 concentration could be a predictive marker of IGHV mutational status, and might be applied for the assessment of prognosis in patients with CLL.

Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications

Serum TK appears to have some clinical value in such solid tumors as prostate cancer, breast cancer, and small-cell lung cancer, whereas it is not a reliable marker of non-small- cell lung cancer and brain tumors.

Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer.

Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.

The results show that s-beta 2M and s-TK independently predict progression-free survival in patients with CLL and IC, and suggest that these prognostic factors may allow an improved prediction of progression- free survival, particularly in early disease stages.

Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.

Chronic lymphocytic leukemia (CLL) shows a remarkably heterogeneous clinical outcome; survival ranges from several months in advanced stages to more than 10 years in early stages. The Binet and Rai

Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.

The serum TK level in CLL patients provides useful prognostic information regarding both response to therapy and length of survival and should be used in planning appropriate therapy.

The role of thymidine kinase in cancer diseases.

Determination of thymidine kinase helps to monitor the follow-up of solid tumours and haematological malignancies as well as indicating the efficacy of adjuvant and palliative chemotherapy.

Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

High TK activity was a strong predictor for short OS and poor response among patients with previously untreated DLBCL treated with R-CHOP.



Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia

It is concluded that S‐TK could be used as a prognostic marker for the individual CLL patient and seems to be useful for longitudinal follow‐up studies of disease status, both in indolent disease and in progressive disease during treatment.

In vitro leukocyte thymidine uptake and prognosis in chronic lymphocytic leukemia.

3H-thymidine uptake in chronic lymphocytic leukaemia cells.

The results indicate that determination of PI might be used as therapy guide since it was normalized during successful treatment and correlated well to variations in clinical disease activity in 8 patients examined at intervals during long term treatment.

The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.

It is concluded that s-dTk could be used both as a prognostic marker and to monitor the effect of therapy in NHL patients.

Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma

S‐TK correlated with the haemoglobin level but did not correlate with sex, age, erythrocyte sedimentation rate, nor with the serum concentrations of creatinine, β2‐microglobulin, Ca or M‐component.

Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humans

The TK activity in sera from patients with both mononucleosis and tumor disease was characterized by electrophoresis and by its ability to utilize cytidine triphosphate as the phosphate donor, and showed that the serum TK has the same properties as the human cytosolar TK1, except in connection with varicella.


The demonstration of TK1 activity in the peripheral blood lymphocytes of clinically aggressive CLL suggests that this isoenzyme may be a useful biochemical marker of such behaviour.

Biochemical characteristics of chronic lymphocytic leukaemia. Glucocorticoid receptors, B and T lymphocyte surface markers, concanavalin A-induced agglutination and thymidine incorporation.

5 out of 6 patients with progressive disease and 3 of 11 with nonprogressive disease had an increased proliferative index, indicating a correlation between this parameter and disease progression, and ConA agglutinability was not correlated to disease activity.

Serum thymidine kinase in acute leukaemia.

The development of a TK assay optimized for TK1, utilizing [1251] iododeoxyuridine as substrate, has been found to facilitate the detection of normal TK kinase activity.

Bi‐weekly chlorambucil treatment of chronic lymphocytic leukemia

It is concluded that bi‐weekly oral administration of chlorambucil is effective therapy for CLL with response rates similar to daily continuous chlor Ambucil.